The hepatitis C revolution part 1: Antiviral treatment options

Current Opinion in Infectious Diseases

Volumn 28, Issue 6, 2015, Pages 563-571

  Thiagarajan, Prarthana ^a   Ryder, Stephen D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

direct acting antiviral agents; genotype 1; hepatitis C; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; HEPACIVIRIN INHIBITOR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; PARITAPREVIR; PEGINTERFERON; PROTEIN INHIBITOR; RIBAVIRIN; RIBAVIRIN DERIVATIVE; SIMEPREVIR; SOFOSBUVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ANTIVIRAL THERAPY; BRADYCARDIA; CLINICAL TRIAL (TOPIC); COMPLETE HEART BLOCK; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG TARGETING; FATIGUE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIFE CYCLE; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; TREATMENT DURATION; VIRAL CLEARANCE; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS REPLICATION; COMBINATION DRUG THERAPY; COMORBIDITY; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84946708425     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000205     Document Type: Review

References (47)

1. Metts J, Carmichael L, Kokor W, Scharffenberg R. Hepatitis C: Prevalence, transmission, screening, and prevention. FP Essent 2014; 427:11-17.
2. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. 2015; http://apps. who. int/iris/bit stream/10665/111747/1/9789241548755-eng. pdf?ua1. [Accessed 9 June 2015]
3. El-Khoury AC, Wallace C, Kimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific and the Americas. J Med Econ 2012; 15:887-896.
4. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16:75-90.
5. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. J Hepatol 2015; 63:199-236.
6. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013; 12:595-610.
7. Chung RT, Gale M, Polyak SJ, et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008; 47:306-320.
8. Testoni B, Levrero M, Durantel D. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? Gut 2014; 63:3-4.
9. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep 2015; 12:68-78.
10. Germain MA, Chatel-Chaix L, Gagne B, et al. Elucidating novel hepatitis C virus/host interactions using combined mass spectrometry and functional genomics approaches. Mol Cell Proteomics 2014; 13:184-203.
11. Breiman A, Grandvaux N, Lin R, et al. Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis Cvirus expression and restoration of signaling by IKKepsilon. J Virol 2005; 79:3969-3978.
12. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
13. Jacobsen McHutchison JG, Dusheiko G, Di Bisceglie AM, et al., ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
14. Wyles DL. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis 2013; 207 (Suppl 1):S33-S39.
15. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61:219-227.
16. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384:1756-1765.
17. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 2015; p. S270.
18. Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria; 2015; p. S264.
19. Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: Academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60:220A.
20. Ehret R, Neifer S, Walter H, et al. Appearance of NS3 Q80K mutation in HCV genotype 1a mono-or HIV/HCV co-infected patients in a Berlin laboratory. J Int AIDS Soc 2014; 17 (4 Suppl 3):19741.
21. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: A ASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 2015; http://www. hcvguidelines. org/. [Accessed 11 September 2015]
22. Zeuzem S, Hezode C, Bronowicki J-PP, et al. Daclatasvir in combination with simeprevir - ribavirin for hepatitis C virus genotype 1 infection. Abstract presented at: 21st conference on retroviruses and opportunistic infections. Topics Antiviral Med 2014; 22 (e-1):15.
23. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment experienced patients with HCV genotype-1 infection: A phase IIb trial. Gastroenterology 2014; 146:430-441.
24. Feld JJ, Ch Moreno. Trinh R, et al. P226: Turquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis. J Viral Hepat 2012; 22:134-135.
25. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56:5387-5396.
26. Gentile I, Buonomo AR, Zappulo E, et al. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag 2014; 10:493-504.
27. Eley T, He B, Chang I, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther 2015; 20:29-37.
28. Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol 2013; 59:375-382.
29. Afdhal N, Zeuzem S, Kwo P, et al., ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
30. Afdhal N, Reddy KR, Nelson DR, et al., ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370:1483-1493.
31. Kowdley KV, Gordon SC, Reddy KR, et al., ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-1888.
32. Reddy KR, Bourlie. , et al. re M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 2015; 62:79-86.
33. Bourlie. , et al. re M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis nonresponsive to previous protease-inhibitor therapy: A randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397-404.
34. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12:671-677.
35. Dore GJ, Lawitz E, Hezode C, et al. Twelve-or 16-week treatment with daclatasvir combined with peginterferon alfa and ribavirin for hepatitis C virus genotype 2 or 3 infection: command GT2/3 study. Hepatology 2012; 56 (Suppl 4):558A-559A.
36. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al., AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
37. Nelson DR, Cooper JN, Lalezari JP, et al., ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127-1135.
38. Pol S, Bourliere M, Lucier S, et al., ANRS/AFEF HEPATHER Study Group. Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS CO22 hepather. In: EASL-The International Liver Congress 2015, 50th Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria. http://www. natap. org/2015/EASL/EASL-44. htm. [Accessed 28 June 2015]
39. Poordad F, Sievert W, Mollison L, et al., UNITY-1 Study Group. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313:1728-1735.
40. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313:1736-1744.
41. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
42. U. S. Food and Drug Administration Recommendations. Hepatitis C treatments containing sofosbuvir in combination with another direct acting antiviral drug: drug safety communication-serious slowing of heart rate when used with antiarrhythmic drug amiodarone. http://www. fda. gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm439662. htm. [Accessed 21 July 2015].
43. Gohil K. Pharmaceutical approval update. Pharm Ther 2014; 39:823-845.
44. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015; 162:407-419.
45. Dufour DR. Hepatitis C-removing barriers to diagnosing the 'silent epidemic'. Clin Chem 2011; 57:939-940.
46. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? BMJ 2015; 350:g7809.
47. Ford N, Swan T, Beyer P, et al. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol 2014; 61 (1 Suppl):S132-S138.